Drawing for RICHTER BIOLOGICS

USPTO serial 79406108

RICHTER BIOLOGICS

Reviewed by CopyMark Law Group

Reg. 7988988Status 700Registered
Filing date
Status date
Registration date
Oct 21, 2025
Examiner
RAMOS, STEPHEN NMN
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with RICHTER BIOLOGICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Haverly MacArthur

Haverly MacArthur Adams and Reese LLP1600 West End AvenueSuite 1400Nashville, TN 37203

Goods and services

ClassDescriptionStatusFirst use
005Biotechnological pharmaceutical preparations for medical use for the treatment of infectious and parasitic diseases, neoplasms, cancer, diseases of the blood and blood-forming organs, immune disorders, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, diseases of the eye, diseases of the ear, diseases of the cardiovascular, respiratory, genitourinary, and digestive systems, diseases and conditions of the skin and subcutaneous tissue and the musculoskeletal system and connective tissue, conditions relating to pregnancy, childbirth and the puerperium, conditions originating in the perinatal period, congenital malformations, deformations and chromosomal abnormalities, and poisoning; biotechnological pharmaceutical preparations for medical purposes for the treatment of infectious and parasitic diseases, neoplasms, cancer, diseases of the blood and blood-forming organs, immune disorders, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, diseases of the eye, diseases of the ear, diseases of the cardiovascular, respiratory, genitourinary, and digestive systems, diseases and conditions of the skin and subcutaneous tissue and the musculoskeletal system and connective tissue, conditions relating to pregnancy, childbirth and the puerperium, conditions originating in the perinatal period, congenital malformations, deformations and chromosomal abnormalities, nucleic recombinant acids for medical useACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 21, 2026FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 30, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Apr 29, 2026FIMPFINAL DISPOSITION PROCESSED—
Mar 26, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Mar 9, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 9, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Jan 21, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 21, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Oct 21, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 2, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 2, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 27, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 28, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 22, 2025XAECEXAMINER'S AMENDMENT ENTERED—
Jul 22, 2025GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jul 22, 2025GNEAEXAMINERS AMENDMENT E-MAILED—
Jul 22, 2025CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 21, 2025XAECEXAMINER'S AMENDMENT ENTERED—
Jul 21, 2025GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jul 21, 2025GNEAEXAMINERS AMENDMENT E-MAILED—
Jul 21, 2025CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 1, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 30, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 30, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 26, 2025RFNTREFUSAL PROCESSED BY IB—
Apr 7, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Apr 7, 2025RFRRREFUSAL PROCESSED BY MPU—
Mar 4, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 3, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 7, 2025DOCKASSIGNED TO EXAMINER—
Oct 17, 2024MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 17, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 10, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance